Oncolytics Biotech Inc.
NASDAQ:ONCYBiotechnology
Healthcare
$0.50 +3.03%
+$0.03 today
- Market cap
- $50.41M
- Beta
- 1.08
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.32
52W Low $0.56High $1.51
Volume 0.38M
Average 1.26M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$39.41M
FY 2025 · Annual
Net Income
-$39.46M
FY 2025 · Annual
Income Statement
CAD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 360.58K | 301.11K | 298.59K | 87K | 70K |
| Gross Profit | (360.58K) | (301.11K) | (298.59K) | (87K) | (70K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 10.31M | 11.85M | 13.12M | 21.65M | 18.27M |
| Selling, General & Admin | 10.26M | 8.53M | 11.62M | 13.34M | 21.15M |
| Operating Expenses | 20.56M | 20.38M | 24.74M | 34.98M | 39.41M |
| Depreciation & Amortization | 360.58K | 301.11K | 298.59K | 102K | 96.05K |
| EBITDA | (20.58M) | (18.71M) | (20.19M) | (34.88M) | (39.41M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (20.93M) | (20.68M) | (25.04M) | (34.98M) | (39.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 99K | 528K | 1.33M | 1.2M | 529.64K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (15.88K) | 1.67M | 4.55M | 3.4M | 61.75K |
| Income Before Tax | (20.94M) | (19.01M) | (20.49M) | (31.58M) | (39.35M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 39.42K | 64.52K | 71.87K | 130K | 108.4K |
| Net Income | (20.98M) | (19.08M) | (20.56M) | (31.71M) | (39.46M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.49) | (0.44) | (0.41) | (0.41) | (0.41) |
| EPS (Diluted) | (0.49) | (0.44) | (0.41) | (0.41) | (0.41) |
| 53.51M | 58.03M | 67.62M | 76.48M | 95.86M | |
| 53.51M | 58.03M | 67.62M | 76.48M | 95.86M |
ONCY Earnings Waterfall · TTM
NASDAQ:ONCY · Revenue to Net Income
Key Ratios
EPS$-0.34
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-5.9
P/S Ratio0.0
Analysis
$0 of revenue converted into -$35.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.34, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Oct 20, 2026 | |
| 8-K | Current report | Oct 14, 2026 | |
| 8-K | Current report | Oct 13, 2026 | |
| DEFA14A | DEFA14A filing | Oct 6, 2026 | |
| DEF 14A | DEF 14A filing | Oct 6, 2026 |
How much revenue does ONCY generate?
Oncolytics Biotech Inc. (ONCY) reported $0.00 of revenue in fiscal 2025.
Is ONCY profitable?
Oncolytics Biotech Inc. (ONCY) reported -$39.46M of net income.
Continue the stock analysis
Jump to another research area for this company.